{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268102","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.496892+00:00","generated_at":"2026-05-16T23:37:22.504833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silence Therapeutics Q3 2025 net loss $21M; divesiran Phase 2 fully enrolled with topline data in 3Q 2026","bullets":["Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.","Net loss $21.0M for Q3 2025 vs $35.5M in Q3 2024, primarily due to lower foreign currency loss.","SANRECO Phase 2 study of divesiran in polycythemia vera fully enrolled (48 patients); topline results expected Q3 2026.","R&D expenses $20.5M (vs $20.2M YoY); G&A expenses $5.8M (vs $7.7M YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268102","json":"https://secwatch.observer/filing/0001193125-25-268102.json","markdown":"https://secwatch.observer/filing/0001193125-25-268102.md","text":"https://secwatch.observer/filing/0001193125-25-268102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/0001193125-25-268102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:37:22.504833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}